Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia-Reference-Cited by-同舟云学术

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

Published:2014-07-04 Issue:12 Volume:93 Page:2011-2018
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

De Astis Enrico,Clavio Marino,Raiola Anna Maria,Ghiso Anna,Guolo Fabio,Minetto Paola,Galaverna Federica,Miglino Maurizio,Di Grazia Carmen,Ballerini Filippo,Marani Carlo,Pastori Giordana,Mitscheunig Laura,Cruciani Fabio,Lovera Davide,Varaldo Riccardo,Ghiggi Chiara,Lemoli Roberto Massimo,Bacigalupo Andrea,Gobbi Marco

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-014-2143-8.pdf

Reference25 articles.

1. Fielding AK, Richards SM, Chopra R et al (2007) Medical Research Council of the United Kingdom Adult ALL Working Party. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 109:944–950

2. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S (2010) Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475–480

3. Tavernier E, Boiron JM, Huguet F, GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907–1914

4. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186–3191

5. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS, Eastern Cooperative Oncology Group LeukemiaCommittee (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148(2):217–225

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia;Transplant Immunology;2024-06

2. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG);Journal of Geriatric Oncology;2023-09

3. A review of treatment options employed in relapsed/refractory AML;Hematology;2023-04-10

4. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients;Leukemia & Lymphoma;2020-03-18

5. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review;Expert Review of Clinical Pharmacology;2019-02-06